2012
Stereotactic Body Radiotherapy for Central Lung Tumors
Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Stereotactic Body Radiotherapy for Central Lung Tumors. Journal Of Thoracic Oncology 2012, 7: 1394-1399. PMID: 22843088, DOI: 10.1097/jto.0b013e3182614bf3.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyCentral lung tumorsBiological equivalent doseLocal recurrenceTracheobronchial treeLung tumorsBody radiotherapyCentral lesionsEquivalent doseGrade 3Baseline pulmonary function testsLarger maximum tumor diameterMedian biological equivalent doseChest wall painGrade 3 dyspneaYale Cancer CenterGrade 2 toxicityLocal control ratePrimary lung cancerPulmonary function testsHigh-grade toxicityMajority of patientsVolume of lungMaximum tumor diameterMaximum point dose
2004
Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non–Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial
Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, Fraser R, Tynan M, Mears A, Rivera MP, Detterbeck FC, Rosenman JG. Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non–Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial. Journal Of Clinical Oncology 2004, 22: 4341-4350. PMID: 15514375, DOI: 10.1200/jco.2004.03.022.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveCamptothecinCarboplatinCarcinoma, Non-Small-Cell LungCombined Modality TherapyFemaleHumansIrinotecanLung NeoplasmsMaleMiddle AgedNeoplasm StagingPaclitaxelRadiotherapy, ConformalRemission InductionSurvival AnalysisTreatment OutcomeConceptsStage III NSCLC patientsCell lung cancerClinical target volumeConcurrent chemotherapyConformal radiation therapyNSCLC patientsPerformance statusLung cancerRadiation therapyDose-escalation phase I trialTarget volumeConventional radiotherapy dosesUnresectable stage IIIAGood performance statusLocal control rateMaximum-tolerated doseDose-limiting toxicityPhase I trialMedian survival timeOverall response rateInitial clinical target volumeInduction chemotherapyFatal hemoptysisLate toxicityStage IIIA